Displaying drugs 2376 - 2400 of 3602 in total
ATG-101
ATG-101 is a novel PD-L1/4-1BB bispecific antibody that was designed to block the binding of immunosuppressive PD-1/PD-L1 and conditionally induce 4-1BB stimulation, thus activating anti-tumor immune effectors, while delivering enhanced anti-tumor activity, with an improved safety profile.
Investigational
HMI-103
HMI-102 is an investigational gene therapy designed to encode the phenylalanine-4-hydroxylase (PAH) gene, mutated in people with phenylketonuria.
Investigational
APT-101
Investigational
ATA-100
ATA-100 is an adeno-associated virus serotype 9 carrying the human Fukutin-Related protein gene and target sequence of the miR-208a
Investigational
CAM-101
CAM-101 is an allogeneic human platelet lysate product depleted of fibrinogen.
Investigational
OTL-102
OTL-102 consists of autologous CD34+ enriched cells that contain hematopoietic stem and progenitor cells transduced ex vivo using a lentiviral vector encoding the human gp91phox gene. It is being investigated for the treatment of X-linked chronic granulomatous disease.
Investigational
HUB-101
Investigational
6,11-DIHYDRO-11-ETHYL-6-METHYL-9-NITRO-5H-PYRIDO[2,3-B][1,5]BENZODIAZEPIN-5-ONE
Experimental
Matched Iupac: … 2-ethyl-10-methyl-14-nitro-2,4,10-triazatricyclo[9.4.0.0^{3,8}]pentadeca-1(15),3(8),4,6,11,13-hexaen- …
Oxazolam
Experimental
Matched Iupac: … 13-chloro-4-methyl-2-phenyl-3-oxa-6,9-diazatricyclo[8.4.0.0^{2,6}]tetradeca-1(10),11,13-trien-8-one …
Atiprimod
Investigational
LJP 1082
LJP 1082 is a Toleragen that is designed to shut down the B cells that produce antibodies to ß2 GP1. LJP 1082 is undergoing trial for for the treatment of stroke, deep-vein thrombosis and other conditions associated with antibody-mediated thrombosis. Antibody-mediated thrombosis, also called antiphospholipid syndrome (APS), is a blood...
Investigational
NCX 1015
NCX 1015 is nitric oxide-releasing derivative of prednisolone developed for the treatment of inflammatory bowel disease (IBD) by NicOx SA.
Investigational
ETC-1001
ETC-1001 is Pfizer’s lead oral small molecule product candidate which is intended to be a chronic treatment for individuals with lipid disorders.
Investigational
PRTX-100
PRTX-100 is a highly-purified form of Staphylococcal Protein A that binds directly to monocytes and a subset of B-cells that are involved in the development and progression of various autoimmune diseases. These binding interactions enable the compound to modulate the function of these cells and restore the balance of the...
Investigational
CUDC-101
CUDC-101 has been used in trials studying the treatment of Cancer, Tumors, Liver Cancer, Breast Cancer, and Gastric Cancer, among others.
Investigational
CXL-1020
CXL-1020 is under investigation in clinical trial NCT01092325 (Safety and Hemodynamic Effects and Pharmacokinetics of CXL-1020 in Patients With Stable Heart Failure).
Investigational
SXR-1096
Investigational
VLX-1005
Investigational
ATSN-101
ATSN-101 is a adeno-associated virus serotype 5 encoding human retinal guanylate cyclase 1 gene (AAV5-GUCY2D)
Investigational
TSHA-105
TSHA-105 is an adeno-associated virus serotype 9 (AAV9) vector with an engineered transgene encoding the human SLC13A5 protein.
Investigational
WU-NK-101
WU-NK-101 is an allogeneic CD3-depleted, CD56-enriched activated natural killer-cell product
Investigational
AOC 1001
AOC 1001 is an antibody oligonucleotide conjugate (AOC), comprised of a human transferrin receptor 1 (TfR1) targeting, effector function null, humanized IgG1 antibody (AV01mAb) conjugated to one small interfering RNA (siRNA).
Investigational
CYNK-101
CYNK-101 is an allogeneic human placental hematopoietic stem cell-derived natural killer (NK) cell therapy product that is genetically modified to express a variant of CD16 (CD16VP).
Investigational
Displaying drugs 2376 - 2400 of 3602 in total